Brian Z Ring1, David R Hout2, Stephan W Morris2, Kasey Lawrence2, Brock L Schweitzer2, Daniel B Bailey2, Brian D Lehmann3, Jennifer A Pietenpol3, Robert S Seitz4. 1. Institute of Personalized and Genomic Medicine, College of Life Science, Huazhong University of Science and Technology, Wuhan, China. 2. Insight Genetics Incorporated, Nashville, Tennessee, USA. 3. Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 4. Insight Genetics Incorporated, Nashville, Tennessee, USA. rseitz@insightgenetics.com.
Since publication of our article [1], we have noticed an error in labelling the p-value of one of the results. The original document read:“The direction of association of BL1 with pCR or minimal residual cancer burden (RCB) in the 2188-gene model was similar (OR = 1.91) but did not reach significance (OR = 0.14).”This has been corrected to:“The direction of association of BL1 with pCR or minimal residual cancer burden (RCB) in the 2188-gene model was similar (OR = 1.91) but did not reach significance (p = 0.14).”We regret the error.
Authors: Brian Z Ring; David R Hout; Stephan W Morris; Kasey Lawrence; Brock L Schweitzer; Daniel B Bailey; Brian D Lehmann; Jennifer A Pietenpol; Robert S Seitz Journal: BMC Cancer Date: 2016-02-23 Impact factor: 4.430